SCHEDULE: Vanguard Reports Zero Stake in Trevi Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Trevi Therapeutics Inc. due to an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Trevi Therapeutics Inc.
• The filing reports 0% beneficial ownership of Trevi Therapeutics Inc. Common Stock by The Vanguard Group.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• These subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated entities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative development for Trevi Therapeutics Inc. due to the reported 0% beneficial ownership by a major institutional investor, even though the underlying reason is an internal restructuring at Vanguard.

Positives

• The internal realignment means that while The Vanguard Group, Inc. no longer directly reports beneficial ownership, its subsidiaries or business divisions will now report separately and continue to pursue the same investment strategies, suggesting potential ongoing, albeit disaggregated, investment interest.

Negatives

• The Vanguard Group, a significant institutional investor, now reports 0% beneficial ownership of Trevi Therapeutics Inc. common stock, indicating a complete divestment or reallocation of direct ownership by this specific reporting entity.

Risks

• The market perception of a major institutional investor, The Vanguard Group, reporting 0% beneficial ownership could lead to negative sentiment or increased selling pressure on Trevi Therapeutics Inc. shares, even if the change is due to internal restructuring rather than a direct investment decision against the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Trevi Therapeutics Inc.'s future performance or The Vanguard Group's future investment intentions beyond the reporting structure change.

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like Vanguard are not uncommon and typically reflect organizational changes rather than a direct investment thesis change regarding the issuer. However, the immediate reporting of 0% beneficial ownership by the primary entity can still be misinterpreted by the market.

Stakeholder Impact

• Shareholders of Trevi Therapeutics Inc. may react negatively to the news of The Vanguard Group reporting 0% beneficial ownership, potentially leading to a decrease in share price due to perceived institutional divestment.

Key Dates

Recommendation

While The Vanguard Group's direct beneficial ownership has dropped to 0%, the filing explicitly states this is due to an internal realignment where subsidiaries will now report separately and pursue the same investment strategies. This suggests the underlying investment thesis may not have changed, but the direct reporting by 'The Vanguard Group' has. Investors should 'hold' to assess if other Vanguard entities report new stakes or if the market overreacts to the initial 0% report, rather than making an immediate 'sell' decision based solely on this structural change.

Keywords

Trevi Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Realignment